EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluating Food and Drug Administration approved gastrointestinal cancer drugs: clinical benefit and trial endpoints over the past two decades

Fares Jamal iD, Oudai Sahvan, Pedro Luiz Serrano Uson Junior, Jeremy C Jones, Fang-Shu Ou iD, Tanios Bekaii-Saab, Mohamad Bassam Sonbol iD

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Fares Jamal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, United States. Hauptthemen laut MEDLINE: Gastrointestinal Neoplasms, Drug Approval, Antineoplastic Agents. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The increasing reliance on accelerated approvals and surrogate endpoints for Food and Drug Administration (FDA) approvals of gastrointestinal (GI) cancer therapies raises concerns about their clinical benefit and long-term patient outcomes. The shift toward single-arm trials in regulatory decisions further complicates treatment evaluation. Material and Methods This retrospective observational study evaluated all FDA approvals for GI cancer therapies from January 2006 through January 2025. Data were extracted from FDA archives, ClinicalTrials.gov, and PubMed. Approvals were categorized by regulatory pathway (accelerated vs regular), trial design (single-arm vs randomized), and primary endpoint (surrogate vs overall survival [OS]). Clinical benefit was assessed based on OS improvement and the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). The primary outcome was the proportion of approvals based on surrogate versus OS endpoints. Secondary outcomes included use of single-arm designs, frequency of accelerated approvals, OS gain, and the proportion meeting ESMO-MCBS substantial benefit (score ≥ 4).

Results

The FDA granted 60 GI cancer drug approvals from 67 trials. Approvals rose from 15 (25%) in 2006-2014 to 45 (75%) in 2015-2025. Single-arm trials increased to 24%, and surrogate endpoints were used in 41.8% (ORR 20.9%, PFS 19.4%). Median OS improvement was 2.1 months (IQR: 1.6-2.65). Only 24.3% of trials met ESMO-MCBS substantial benefit. Of 15 accelerated approvals, 66.7% remained pending, 13.3% received full approval, and 20% were withdrawn.

Conclusion

Expedited approvals have improved drug access in GI oncology, but modest benefits highlight the need to balance speed with outcomes that truly matter to patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal NeoplasmsDrug ApprovalAntineoplastic AgentsHumansUnited States Food and Drug AdministrationUnited StatesRetrospective StudiesClinical Trials as TopicEndpoint Determination

Stichwörter der Autor:innen

ESMO-MCBSFDA approvalsaccelerated approvalsgastrointestinal cancersurrogate endpoints

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, United States.
  • Division of Hematology/Oncology, Mayo Clinic Cancer Center, Mayo Clinic, Jacksonville, FL 32224, United States.
  • Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, United States.

ORCID-Profile: Fares Jamal, Fang-Shu Ou, Mohamad Bassam Sonbol

Zitieren

APA

Jamal, F., Sahvan, O., Junior, P. L. S. U., Jones, J. C., Ou, F. S., Bekaii-Saab, T., & Sonbol, M. B. (2025). Evaluating Food and Drug Administration approved gastrointestinal cancer drugs: clinical benefit and trial endpoints over the past two decades. The Oncologist. https://doi.org/10.1093/oncolo/oyaf381

Vancouver

Jamal F, Sahvan O, Junior PLSU, Jones JC, Ou FS, Bekaii-Saab T, et al. Evaluating Food and Drug Administration approved gastrointestinal cancer drugs: clinical benefit and trial endpoints over the past two decades. The Oncologist. 2025. doi:10.1093/oncolo/oyaf381

BibTeX
@article{Jamal2025,
  author = {Jamal, Fares and Sahvan, Oudai and Junior, Pedro Luiz Serrano Uson and Jones, Jeremy C and Ou, Fang-Shu and Bekaii-Saab, Tanios and Sonbol, Mohamad Bassam},
  title = {Evaluating Food and Drug Administration approved gastrointestinal cancer drugs: clinical benefit and trial endpoints over the past two decades},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf381}
}
Kostenlos starten →